ALK inhibitors in the treatment of advanced NSCLC.

@article{Gridelli2014ALKII,
  title={ALK inhibitors in the treatment of advanced NSCLC.},
  author={Cesare Gridelli and Solange Peters and Assunta Sgambato and Francesca Casaluce and Araba A. Adjei and Fortunato Ciardiello},
  journal={Cancer treatment reviews},
  year={2014},
  volume={40 2},
  pages={300-6}
}
Pharmacologic agents that target protein products of oncogenes in tumors are playing an increasing clinical role in the treatment of cancer. Currently, the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) represent the standard of care for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations. Subsequently other genetic abnormalities with "driver" characteristics - implying transforming and tumor maintenance… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS